315 related articles for article (PubMed ID: 27190080)
1. Considerably decreased risk of cardiovascular disease with combined reductions in HbA1c, blood pressure and blood lipids in type 2 diabetes: Report from the Swedish National Diabetes Register.
Eeg-Olofsson K; Zethelius B; Gudbjörnsdottir S; Eliasson B; Svensson AM; Cederholm J
Diab Vasc Dis Res; 2016 Jul; 13(4):268-77. PubMed ID: 27190080
[TBL] [Abstract][Full Text] [Related]
2. Effect of Multifactorial Treatment Targets and Relative Importance of Hemoglobin A1c, Blood Pressure, and Low-Density Lipoprotein-Cholesterol on Cardiovascular Diseases in Chinese Primary Care Patients With Type 2 Diabetes Mellitus: A Population-Based Retrospective Cohort Study.
Wan EYF; Fung CSC; Yu EYT; Chin WY; Fong DYT; Chan AKC; Lam CLK
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862945
[TBL] [Abstract][Full Text] [Related]
3. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients.
Ji L; Hu D; Pan C; Weng J; Huo Y; Ma C; Mu Y; Hao C; Ji Q; Ran X; Su B; Zhuo H; Fox KA; Weber M; Zhang D; ;
Am J Med; 2013 Oct; 126(10):925.e11-22. PubMed ID: 23810406
[TBL] [Abstract][Full Text] [Related]
4. Decreased systolic blood pressure is associated with increased risk of all-cause mortality in patients with type 2 diabetes and renal impairment: A nationwide longitudinal observational study of 27,732 patients based on the Swedish National Diabetes Register.
Svensson MK; Afghahi H; Franzen S; Björk S; Gudbjörnsdottir S; Svensson AM; Eliasson B
Diab Vasc Dis Res; 2017 May; 14(3):226-235. PubMed ID: 28467201
[TBL] [Abstract][Full Text] [Related]
5. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR).
Eeg-Olofsson K; Cederholm J; Nilsson PM; Zethelius B; Svensson AM; Gudbjörnsdóttir S; Eliasson B
J Intern Med; 2010 Nov; 268(5):471-82. PubMed ID: 20804517
[TBL] [Abstract][Full Text] [Related]
6. HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target.
Ceriello A; Lucisano G; Prattichizzo F; La Grotta R; Franzén S; Svensson AM; Eliasson B; Nicolucci A
Cardiovasc Diabetol; 2022 Jan; 21(1):13. PubMed ID: 35073913
[TBL] [Abstract][Full Text] [Related]
7. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
Krishnappa M; Patil K; Parmar K; Trivedi P; Mody N; Shah C; Faldu K; Maroo S; ; Parmar D
Cardiovasc Diabetol; 2020 Jun; 19(1):93. PubMed ID: 32560724
[TBL] [Abstract][Full Text] [Related]
8. Mortality associated with less intense risk-factor control among adults with diabetes in the United States.
Saydah SH; Gregg EW; Kahn HS; Ali MK
Prim Care Diabetes; 2018 Feb; 12(1):3-12. PubMed ID: 28797537
[TBL] [Abstract][Full Text] [Related]
9. Level of physical activity associated with risk of cardiovascular diseases and mortality in patients with type-2 diabetes: report from the Swedish National Diabetes Register.
Zethelius B; Gudbjörnsdottir S; Eliasson B; Eeg-Olofsson K; Cederholm J;
Eur J Prev Cardiol; 2014 Feb; 21(2):244-51. PubMed ID: 24227183
[TBL] [Abstract][Full Text] [Related]
10. Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
Menon V; Kumar A; Patel DR; John JS; Wolski KE; McErlean E; Riesmeyer JS; Weerakkody G; Ruotolo G; Cremer PC; Nicholls SJ; Lincoff AM; Nissen SE
J Am Heart Assoc; 2020 Jan; 9(1):e014328. PubMed ID: 31852422
[TBL] [Abstract][Full Text] [Related]
11. Effect of improved fitness beyond weight loss on cardiovascular risk factors in individuals with type 2 diabetes in the Look AHEAD study.
Gibbs BB; Brancati FL; Chen H; Coday M; Jakicic JM; Lewis CE; Stewart KJ; Clark JM;
Eur J Prev Cardiol; 2014 May; 21(5):608-17. PubMed ID: 23012688
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of Newly Diagnosed Type 2 Diabetes in Chinese Older Adults: A National Prospective Cohort Study.
Lv F; Cai X; Hu D; Pan C; Zhang D; Xu J; Ji L
J Diabetes Res; 2019; 2019():5631620. PubMed ID: 31828163
[TBL] [Abstract][Full Text] [Related]
13. Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR).
Cederholm J; Zethelius B; Nilsson PM; Eeg-Olofsson K; Eliasson B; Gudbjörnsdottir S;
Diabetes Res Clin Pract; 2009 Oct; 86(1):74-81. PubMed ID: 19679369
[TBL] [Abstract][Full Text] [Related]
14. The triglycerides-to-HDL-cholesterol ratio and cardiovascular disease risk in obese patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR).
Eeg-Olofsson K; Gudbjörnsdottir S; Eliasson B; Zethelius B; Cederholm J;
Diabetes Res Clin Pract; 2014 Oct; 106(1):136-44. PubMed ID: 25108897
[TBL] [Abstract][Full Text] [Related]
15. National survey: Evaluation of cardiovascular risk factors in Thai patients with type 2 diabetes and chronic kidney disease after the development of cardiovascular disease.
Changsirikulchai S; Sangthawan P; Janma J; Sripaiboonkij N; Rattanamongkolgul S; Thinkhamrop B
Nephrology (Carlton); 2018 Jan; 23(1):53-59. PubMed ID: 27608176
[TBL] [Abstract][Full Text] [Related]
16. Personalised treatment targets in type 2 diabetes patients: The Dutch approach.
Boels AM; Hart HE; Rutten GE; Vos RC
Prim Care Diabetes; 2017 Feb; 11(1):71-77. PubMed ID: 27633894
[TBL] [Abstract][Full Text] [Related]
17. High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus.
Artha IMJR; Bhargah A; Dharmawan NK; Pande UW; Triyana KA; Mahariski PA; Yuwono J; Bhargah V; Prabawa IPY; Manuaba IBAP; Rina IK
Vasc Health Risk Manag; 2019; 15():149-157. PubMed ID: 31239693
[No Abstract] [Full Text] [Related]
18. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
Lugner M; Sattar N; Miftaraj M; Ekelund J; Franzén S; Svensson AM; Eliasson B
Cardiovasc Diabetol; 2021 Mar; 20(1):67. PubMed ID: 33752680
[TBL] [Abstract][Full Text] [Related]
19. Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register.
Gudbjörnsdottir S; Eliasson B; Eeg-Olofsson K; Zethelius B; Cederholm J;
Diabetologia; 2011 Oct; 54(10):2544-51. PubMed ID: 21674176
[TBL] [Abstract][Full Text] [Related]
20. Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary.
Mark L; Vallejo-Vaz AJ; Reiber I; Paragh G; Kondapally Seshasai SR; Ray KK
Atherosclerosis; 2015 Jul; 241(1):62-8. PubMed ID: 25966441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
